This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers
Quadripartite call to action for One Health for a safer world
Published on 27 March 2023

Joint Statement
QU Dongyu, Director-General, FAO
Inger Andersen, Executive Director, UNEP
Tedros Adhanom Ghebreyesus, Director-General, WHO
Monique Eloit, Director-General, WOAH

Paris/Rome/Geneva/Nairobi – Recent international health emergencies such as COVID-19 pandemic, mpox, Ebola outbreaks, and continued threats of other zoonotic diseases, food safety, antimicrobial resistance (AMR) challenges, as well as ecosystem degradation and climate change clearly demonstrate the need for resilient health systems and accelerated global action. One Health is seen as the main approach for tackling these pressing and complex challenges facing our society.

At their first annual face-to-face meeting today, the heads of the Quadripartite organizations working on One Health issued an unprecedented call for enhanced global action.

The Quadripartite aims to achieve together what no one sector can achieve alone, and it consists of four main agencies: the Food and Agriculture Organization of the United Nations (FAO), United Nations Environment Programme (UNEP), World Health Organization (WHO) and World Organisation for Animal Health (WOAH).

Call to action
Stressing the need for enhanced collaboration and commitment to translate the One Health approach into policy action in all countries, the Quadripartite leaders urge all countries and key stakeholders to promote and undertake the following priority actions:

1. **Prioritize One Health in the international political agenda, increase understanding and advocate for the adoption and promotion of the enhanced intersectoral health governance.** The One Health approach should notably serve as a guiding principle in global mechanisms; including in the new pandemic instrument and the pandemic fund to strengthen pandemic prevention, preparedness and response;

2. **Strengthen national One Health policies, strategies and plans,** costed and prioritized in line with the Quadripartite One Health Joint Plan of Action (OH JPA), to foster wider implementation across relevant sectors and at all levels;

3. **Accelerate the implementation of One Health plans,** including supporting of national One Health governance and multisectoral coordination mechanisms, development of situation analyses, stakeholder mapping, priority setting, and metrics for One Health monitoring and evaluation frameworks;

4. **Build intersectoral One Health workforces** that have the skills, capacities and capabilities to prevent, detect, control, and respond to health threats in a timely and effective way, by strengthening joint pre-service and continuing education for human, animal, and environmental health workforces;
5. **Strengthen and sustain prevention of pandemics and health threats at source**, targeting activities and places that increase the risk of zoonotic spillover between animals to humans;

6. **Encourage and strengthen One Health scientific knowledge and evidence creation and exchange**, research and development, technology transfer and sharing and integrating of information and data and facilitate access to new tools and technologies; and

7. **Increase investment and financing of One Health strategies and plans** ensuring scaled up implementation at all levels, including funding for prevention of health threats at source.

To build one healthier planet we need urgent action to galvanize vital political commitments, greater investment and multisectoral collaboration at every level.

The Quadripartite has been playing a central role in promoting and coordinating a global One Health approach, in line with the OH JPA [1] which was launched in October 2022. To further support countries and governments putting the One Health approach into practice, the Quadripartite partners are developing an OH JPA implementation guide to be released in 2023.

---

**SAGE March 2023 meeting highlights published**

29 March 2023

**Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization**

20-22 March 2023

*(The full report will be published in the Weekly Epidemiological Record on 2 June 2023, and only the wording of the full report should be considered final)*

**Session 1**

**Report from the Department of Immunization, Vaccines, and Biologicals.**

- The COVID-19 pandemic vaccination response still requires efforts to reduce inequities, reach high-priority groups, and close coverage gaps.
- Disruptive measles and other disease outbreaks highlight the need for catch-up vaccination and for enhancing preparedness for outbreak response.
- To get back on the trajectory for achieving the Immunization Agenda 2030 (IA2030) goals and targets, a 3-prong approach to provide catch-up vaccination to children who missed scheduled doses, restore coverage, and strengthen immunization programmes is planned.
- Innovations developed for the COVID-19 response and a pipeline of vaccines and innovative technologies and platforms will support actions to strengthen vaccination across the life course.
- The highest priorities for 2023-2025 are the zero-dose child agenda and routine immunization strengthening (which includes catchup, and with special attention on measles, yellow fever, other outbreak prone diseases, and polio), preparedness and response to outbreaks, revitalization of human papillomavirus (HPV) vaccination, integration of COVID-19 vaccination into routine immunization and Primary Health Care (PHC), and malaria vaccine introduction in African countries.

**Update from Gavi, the Vaccine Alliance.**

- The Gavi 5.1 strategy reaffirms the core priorities in the Gavi 5.0 strategy and additionally includes support for ongoing COVID-19 vaccination in priority use groups and an evolution of its support in pandemic preparedness.
• The Gavi “must-win” priorities for 2023 include the restoration of routine immunization, expansion of malaria vaccination, the relaunch of HPV vaccination, and support for targeted COVID-19 vaccination and its integration with other health services.
• The next update of the vaccine investment strategy to inform Gavi investments in the Gavi 6.0 strategy is expected to be completed in 2024.
• Gavi will continue to support the introduction and use of inactivated poliovirus vaccine (IPV) and preventive and outbreak response vaccination for measles and rubella in eligible countries.

Session 2
Regional reports with a focus on measles.
• SAGE reviewed data on the status of measles elimination in each region, including the impact of the COVID-19 pandemic, and the challenges faced.
• All WHO regions have observed an increase in measles cases in 2022 and the accumulation of immunity gaps has increased the risk of outbreaks. Difficulties with delivering vaccines in conflict-affected settings, weak health systems, competing priorities, and inadequate financing are the challenges faced.
• Delays in securing funding are impeding efforts to conduct preventive vaccination campaigns and mount a timely outbreak response.
• Surveillance quality declined in all regions during the pandemic though there are signs of recovery in several countries.
• SAGE noted the need to review and update policies on age eligibility for measles vaccination to enable catch-up, accelerate the development and use of new technologies and innovations, and review the evidence to support policy recommendations for vaccination of infants below six months and during pregnancy.

Session 3
Partnering with regions and countries to identify priority pathogens for new vaccines.
• WHO in collaboration with all its regional offices has undertaken a process to define targets for new vaccine development for endemic pathogens. Those targets will eventually be included as monitoring indicators for Strategic Priority 7 (on research and development) of Immunization Agenda 2030.
• The process included a multi-criteria decision analysis (MCDA) method with a preference survey to weight the prioritization criteria, followed by regional consultations to review the outcomes and develop a list of priority pathogens for each region.
  1. using the Potentially All Pairwise Rankings of all possible Alternatives (PAPRIKA).
  https://www.1000minds.com/paprika (accessed 25/03/2023)
• Early results show consensus that tuberculosis, human immunodeficiency virus (HIV), and pathogens that exhibit high levels of antimicrobial resistance such as Klebsiella pneumoniae are important across all regions.
• Other pathogens targets including such as Streptococcus pyogenes (Group A streptococcus), Shigella, and respiratory syncytial virus (RSV) were identified as important by four or more regions and Plasmodium falciparum by the African region.
• Work is ongoing to finalize these priority targets for vaccine development to inform regional, national, and global research and development strategies, and investment.

Session 4
Roadmap for COVID-19 vaccination in the Omicron era.
• SAGE discussed an updated roadmap on uses of COVID-19 vaccines considering the evolving public health needs in the era of the Omicron variant and high population-level immunity.
The update is based on the scenario that assumes the virus will continue to evolve but cause less severe disease with possible surges in infections that will require periodic booster doses of the vaccine to protect the highest priority group, and the recommendations apply only in the context of this epidemiological scenario.

The update considers the steep increase in the seroprevalence of SARS CoV2 antibodies globally in all age groups, indicating high levels of immunity due to infection-induced, vaccine-induced, or hybrid immunity.

The update also considers the overall decline in disease severity, including post-COVID conditions, and acknowledges the programmatic and financial opportunity cost of COVID-19 vaccination.

A simplified risk classification now includes three risk groups (high, medium, and low) and proposes a differentiated approach for the provision of the primary series and additional booster doses for each risk group.

Very briefly, the key recommendations in the updated roadmap comprise: (i) administration of additional boosters doses (beyond the first booster dose) for high-priority groups, including frontline health workers 12 months after the previous booster dose; (ii) additional booster doses are not routinely recommended for the medium risk group; (iii) administration of a booster dose during pregnancy if the last dose was given more than 6 months earlier; and (iv) considering the primary series and booster dose for healthy children and adolescents only within country context, including disease burden in this age group, cost-effectiveness, other health or programmatic priorities, and opportunity costs. The updated roadmap with more details on the recommendations is to be published shortly.

**Session 5**

*Status of new tuberculosis vaccine candidates intended for adults and adolescents: preparing the pathway for use.*

- Tuberculosis (TB) is a leading infectious killer and is estimated to cause over 10 million cases and 1.6 million deaths in 2021. The COVID-19 pandemic has reversed years of progress made in the fight against TB.
- A vaccine that prevents TB in adolescents and adults is needed to reduce the disease burden among them and transmission to other target age groups. Several candidates are in late-stage clinical trials and a few vaccines could receive regulatory authorization within 3 years.
- SAGE was provided with preliminary clinical trial data on a promising TB vaccine candidate for adults and adolescents – M72/AS01E.
- SAGE encouraged investigators and funders to explore research design approaches to demonstrate the prevention of Mtb infection in infection-naive individuals in the context of the upcoming efficacy trials.
- SAGE proposed that a cluster randomized trial to assess the potential indirect effect of M72/AS01E be considered in parallel to the phase 3 trial, and studies to accelerate recommendations for use in adolescents below 15 years of age, ease implementation and improve cost-effectiveness.

**Session 6**

*Polio eradication.*

- SAGE was presented with an epidemiological update on poliomyelitis, data to inform vaccination strategies for areas with persistent poliovirus transmission and the use of the novel type 2 oral poliovirus vaccine (nOPV2) at shorter intervals for outbreak response, and the report from the Polio SAGE Working Group on restricting the use of Sabin oral poliovirus vaccines (OPV).
- SAGE was pleased to note the reduction in type 1 wild poliovirus (WPV1) cases in the endemic countries. However, SAGE expressed concern about the persistence of circulating vaccine-derived
poliovirus (cVDPV) type 2 in Africa and a sharp increase in cVDPV type 1 cases in several countries which highlighted the urgent need to improve routine immunization coverage to mitigate this risk in the short and longer term.

- To its previous recommendation of conducting quality outbreak response without delay, SAGE recommended the preferential use of nOPV2 vaccine for a cVDPV type 2 outbreak response with oral vaccines, and that type 2 Sabin OPV should only be used in exceptional circumstances.
- SAGE recommended that in areas of persistent poliovirus circulation, an additional IPV (full or fractional dose) campaign should be conducted to supplement OPV campaigns as a means to enhance mucosal immunity and reduce the likelihood of ongoing poliovirus circulation.
- SAGE recommended a flexible approach using nOPV2 for outbreak response in shorter than 4-week intervals but maintaining a minimum 1-week interval if dictated by programme needs.

Session 7
Malaria vaccination.
- SAGE was presented with an update on the malaria vaccine implementation programme (MVIP), and the plans for future roll-out and the Framework for allocation of currently limited supply. SAGE noted that MVIP will end in 2023, having answered the key questions for which the programme was established, i.e., showing vaccine delivery in routine immunization programmes is feasible, the vaccine is safe, and the impact is high. Vaccine introduction resulted in substantial reduction in severe malaria and all-cause mortality among children eligible to receive the vaccine.
- There is a high demand for the vaccine with at least 28 countries expressing interest in introducing the vaccine. Of these, 15 countries already submitted an application to Gavi for support, and more than 15 additional applications are expected later this year. Vaccine supply remains highly constrained and will be made available based on the Framework for allocation of limited supply.
- Evidence and options for the minimal interval between doses 3 and 4 for vaccination in areas of highly seasonal malaria transmission or perennial transmission with seasonal peaks were presented. SAGE concurred with the SAGE and Malaria Policy Advisory Group (MPAG) Working Group (WG) on malaria vaccines proposal to allow for flexibility in the immunization schedule and to reduce the minimum interval between the doses 3 and 4 to 6 months to optimize impact.
- The SAGE MPAG WG is in the process of reviewing the R21 Matrix M malaria vaccine, which is in the late stages of clinical development. Initial results presented appear promising. The safety of the vaccine will be reviewed by the WHO Global Advisory Committee on Vaccine Safety (GACVS). The next SAGE/MPAG malaria vaccine WG review will occur later this year when 18-month follow-up for seasonal delivery and 12-month follow-up for age-based delivery are completed.

------

SAGE updates COVID-19 vaccination guidance
28 March 2023
News release
Following its 20-23 March meeting, WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) revised the roadmap for prioritizing the use of COVID-19 vaccines, to reflect the impact of Omicron and high population-level immunity due to infection and vaccination.

The roadmap continues SAGE’s prioritization of protecting populations at the greatest risk of death and severe disease from SARS-CoV-2 infection and its focus on maintaining resilient health systems. The roadmap newly considers the cost-effectiveness of COVID-19 vaccination for those at lower risk – namely healthy children and adolescents – compared to other health
interventions. The roadmap also includes revised recommendations on additional booster doses and the spacing of boosters. The current COVID-19 vaccines’ reduction of post-COVID conditions is also considered but the evidence on the extent of their impact is inconsistent.

“Updated to reflect that much of the population is either vaccinated or previously infected with COVID-19, or both, the revised roadmap reemphasizes the importance of vaccinating those still at risk of severe disease, mostly older adults and those with underlying conditions, including with additional boosters,” stated SAGE Chair Dr Hanna Nohynek. “Countries should consider their specific context in deciding whether to continue vaccinating low risk groups, like healthy children and adolescents, while not compromising the routine vaccines that are so crucial for the health and well-being of this age group.”

The revised roadmap outlines three priority-use groups for COVID-19 vaccination: high, medium, and low. These priority groups are principally based on risk of severe disease and death, and consider vaccine performance, cost-effectiveness, programmatic factors and community acceptance.

The high priority group includes older adults; younger adults with significant comorbidities (e.g. diabetes and heart disease); people with immunocompromising conditions (e.g. people living with HIV and transplant recipients), including children aged 6 months and older; pregnant persons; and frontline health workers.

For the high priority group, SAGE recommends an additional booster of either 6 or 12 months after the last dose, with the timeframe depending on factors such as age and immunocompromising conditions. All the COVID-19 vaccine recommendations are time-limited, applying for the current epidemiological scenario only, and so the additional booster recommendations should not be seen as for continued annual COVID-19 vaccine boosters. The aim is to serve countries planning for the near- to mid-term.

The medium priority group includes healthy adults – usually under the age of 50-60 – without comorbidities and children and adolescents with comorbidities. SAGE recommends primary series and first booster doses for the medium priority group. Although additional boosters are safe for this group, SAGE does not routinely recommend them, given the comparatively low public health returns.

The low priority group includes healthy children and adolescents aged 6 months to 17 years. Primary and booster doses are safe and effective in children and adolescents. However, considering the low burden of disease, SAGE urges countries considering vaccination of this age group to base their decisions on contextual factors, such as the disease burden, cost effectiveness, and other health or programmatic priorities and opportunity costs.

The public health impact of vaccinating healthy children and adolescents is comparatively much lower than the established benefits of traditional essential vaccines for children – such as the rotavirus, measles, and pneumococcal conjugate vaccines – and of COVID-19 vaccines for high and medium priority groups. Children with immunocompromising conditions and comorbidities do face a higher risk of severe COVID-19, so are included in the high and medium priority groups respectively.

Though low overall, the burden of severe COVID-19 in infants under 6 months is still higher than in children aged 6 months to 5 years. Vaccinating pregnant persons – including with an additional dose if
more than 6 months have passed since the last dose – protects both them and the fetus, while helping to reduce the likelihood of hospitalization of infants for COVID-19.

Countries that already have a policy in place for additional boosters should assess the evolving need based on national disease burden, cost effectiveness and opportunity costs.

Separate to the roadmap, SAGE also updated their recommendations on bivalent COVID-19 vaccines, now recommending that countries can consider using BA.5 bivalent mRNA vaccine for the primary series...

30 March 2023

WHO SAGE Roadmap for prioritizing uses of COVID-19 vaccines

::::::

::::::

Cholera

Multi-country outbreak of cholera, External situation report #1 - 28 March 2023

Overview
Since the last disease outbreak news on the global cholera situation was published on 11 February 2023, the global situation has further deteriorated with four new countries reporting outbreaks. In total, 24 countries are reporting cases as of 20 March. The overall capacity to respond to the multiple and simultaneous outbreaks continues to be strained due to the global lack of resources, including shortages of the oral cholera vaccine, as well as overstretched public health and medical personnel, who are dealing with multiple disease outbreaks and other health emergencies at the same time. Based on the current situation, WHO assesses the risk at the global level as very high.

::::::

::::::

PHEIC

Coronavirus [COVID-19] - WHO
Public Health Emergency of International Concern (PHEIC)
https://www.who.int/emergencies/diseases/novel-coronavirus-2019

Weekly Epidemiological and Operational updates
Last update: 29 March 2023
Confirmed cases :: 761 402 282
Confirmed deaths :: 6 887 000
Vaccine doses administered: 13 331 975 343

Weekly epidemiological update on COVID-19 - 30 March 2023
Overview
Globally, nearly 3.6 million new cases and over 25,000 deaths were reported in the last 28 days (27 February to 26 March 2023), a decrease of 27% and 39%, respectively, compared to the previous 28 days. Despite this overall downward trend, it is important to note that several countries have recently reported significant increases in cases. As of 26 March 2023, over 761 million confirmed cases and over 6.8 million deaths have been reported globally.

Our World in Data
Coronavirus (COVID-19) Vaccinations [Accessed 01 Apr 2023]
:: 69.8% of the world population has received at least one dose of a COVID-19 vaccine.
:: 13.36 billion doses have been administered globally, and 608,056 are now administered each day.
:: 28.5% of people in low-income countries have received at least one dose.

COVID Vaccines – OCHA:: HDX

COVID-19 Data Explorer: Global Humanitarian Operations
COVID-19 Vaccine Roll-out
Apr 1, 2023 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA
Global COVID-19 Figures: 125M total confirmed cases; 2.3M total confirmed deaths
Global vaccines administered: 13.4B
Number of Countries: 28
COVAX Allocations Round 4-9 (Number of Doses): 170M
COVAX Delivered (Number of Doses): 390M
Other Delivered (Number of Doses): 430M
Total Delivered (Number of Doses): 830M
Total Administered (Number of Doses): 600M

Global Dashboard on COVID-19 Vaccine Equity
The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 01 Apr 2023]: https://data.undp.org/vaccine-equity/
See also visualization on Vaccine Access and Vaccine Affordability

Duke – Launch and Scale Speedometer
The Race for Global COVID-19 Vaccine Equity
See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research
Overview of donations by top 10 donating countries

Bar chart is ordered by total number of doses pledged. Donor charts are ordered by proportion of pledged donations shipped.

United States: 86% shipped
China: 83% shipped
France: 73% shipped
Germany: 69% shipped
United Kingdom: 69% shipped
Italy: 68% shipped
Australia: 67% shipped
Japan: 59% shipped
Canada: 59% shipped
Spain: 59% shipped

Remaining: 603,950,208
Total Shipped: 1,543,936,950

Global COVID-19 Access Tracker
https://www.covid19globaltracker.org/

Last Update on Mar 31, 2023
Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

**European Medicines Agency [EMA]**

*News & Press Releases*

**News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27 - 30 March 2023 (new)**

CHMP, Last updated: 31/03/2023

The CHMP recommended authorising the COVID-19 vaccine Bimervax (previously COVID-19 Vaccine HIPRA) as a booster in people aged 16 years and older who have previously been vaccinated with an mRNA COVID-19 vaccine. It is the eighth vaccine recommended in the European Union (EU) for protecting against COVID-19 and, together with the vaccines already authorised, will support vaccination campaigns in EU Member States during the pandemic. An overview of all the COVID-19 vaccines authorised in the EU is available on EMA’s website. See more information in the news announcement in the grid below.

**News: EMA recommends approval of Bimervax as a COVID-19 booster vaccine (new)**

CHMP, Last updated: 30/03/2023

---

**European Centre for Disease Prevention and Control**


*News/Updates/Reports [Selected]*

**News**

**Weekly COVID-19 country overview**

Epidemiological update - 31 Mar 2023
Africa: COVID-19 – Announcements/Regulatory Actions/Deployment
https://africacdc.org/covid-19-vaccination/

Africa CDC COVID-19 Vaccine Dashboard
Safeguarding Africa's Health

Vaccine Administration based on Eligible Population (Click to View Entire Population)

1101.8M
Vaccine Doses Received
95.7%
% Doses Utilized

1054.1M
Vaccine Doses Administered
49.9%
% Coverage (Fully Vaccinated)

(Last Update: March 23, 2023)

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
No new digest content identified. Last press release issued 31.08.2022.

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Government of India – Press Information Bureau
Latest Press Releases
No new digest content identified.

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Press Releases
No new digest content identified.
Clinical Guidance for Management of Adult COVID-19 Patients (updated on 28th March 2023)

PHEIC
Mpox
Public Health Emergency of International Concern (PHEIC)
https://www.who.int/emergencies/situations/monkeypox-oubreak-2022

Latest Situation Report:
Multi-country outbreak of mpox, External situation report #19 - 30 March 2023

Overview
This is the 19th situation report for the multi-country outbreak of mpox, which provides details on the latest epidemiology, a summary of mpox in people living with HIV, a special focus on the study of the animal reservoir of monkeypox virus in Nigeria, and an update from the WHO African region.

PHEIC
Polio

Polio this week as of 29 March 2023 - GPEI
Headlines [Selected]
:: This month marks two years since novel oral polio vaccine type 2 (nOPV2) began its field rollout. We interviewed co-leads of GPEI’s nOPV Working Group – Simona Zipursky (WHO) and Ananda Bandyopadhyay (BMGF) – on the journey and the vaccine’s performance so far. Approximately 590 million doses of nOPV2 have been administered across 28 countries under its WHO Emergency Use Listing (EUL) to date. An additional 13 countries have met the requirements for nOPV2 use in the event of an outbreak. For more information on nOPV2, visit: www.polioeradication.org/nOPV2
:: This month marks two years since novel oral polio vaccine type 2 (nOPV2) began its field rollout. We interviewed co-leads of GPEI’s nOPV Working Group – Simona Zipursky (WHO) and Ananda
Bandyopadhyay (BMGF) – on the journey and the vaccine’s performance so far. Approximately 590 million doses of nOPV2 have been administered across 28 countries under its WHO Emergency Use Listing (EUL) to date. An additional 13 countries have met the requirements for nOPV2 use in the event of an outbreak. For more information on nOPV2, visit: www.polioeradication.org/nOPV2

Summary of new polioviruses this week:
- Afghanistan: one wild poliovirus type 1 (WPV1)-positive environmental sample
- Central African Republic (CAR): five circulating vaccine-derived poliovirus type 2 (cVDPV2) cases
- Chad: two cVDPV2 cases
- Democratic Republic of the Congo (DR Congo): 11 circulating vaccine-derived poliovirus type 1 (cVDPV1) cases and 22 cVDPV2 cases
- Madagascar: three cVDPV1-positive environmental samples
- Nigeria: two cVDPV2-positive environmental samples

UN OCHA – Current Emergencies
Current Corporate Emergencies

Afghanistan
Editor's Note:
We observe that OCHA has removed Afghanistan from its listing of “Current Emergencies.” We did not identify any explanation for its removal.

Northern Ethiopia
No new digest content identified.

Somalia
No new digest content identified.

Türkiye/Syria Earthquakes
31 Mar 2023
Today’s top news: Ethiopia, Syria

Ukraine
Last Updated: 10 Feb 2023

WHO & Regional Offices [to 01 Apr 2023]
https://www.who.int/news
Selected News/Announcements/Statements
31 March 2023 Departmental news
WHO and the Inter-Parliamentary Union launch a new handbook on Universal Health Coverage
30 March 2023    Departmental news
WHO welcomes signing of sublicences with three manufacturers to produce long-acting injectable cabotegravir for HIV prevention

30 March 2023    Departmental news
WHO applauds Indian leadership on ending TB

29 March 2023    News release
WHO certifies Azerbaijan and Tajikistan as malaria-free

29 March 2023    Departmental news
SAGE March 2023 meeting highlights published

28 March 2023    News release
SAGE updates COVID-19 vaccination guidance

28 March 2023    Departmental news
WHO initiates building a global curriculum for infodemic management

WHO Regional Offices
Selected Press Releases, Announcements

WHO African Region
No new digest content identified.

WHO Region of the Americas PAHO
:: SAGE updates COVID-19 vaccination guidance
   28 March 2023 (PAHO) – Following its 20-23 March meeting, WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) revised the roadmap for prioritizing the use of COVID-19 vaccines, to reflect the impact of Omicron and high population-level immunity due to infection and vaccination. The roadmap continues SAGE’s prioritization of...
:: Regional survey reveals extensive disruptions to NCD care in the Americas during COVID-19 pandemic
   Cancer screening and management of diabetes and hypertension among main services impacted. Washington D.C. 27 March 2023 (PAHO) – Extensive disruptions in the diagnosis and management of non-communicable diseases (NCDs) in the Americas during the COVID-19 pandemic had a “significant adverse impact on the region” warns a new study from the Pan...

WHO South-East Asia Region SEARO
No new digest content identified.

WHO European Region EURO
:: 30 March 2023    News release
Funding the search for answers about post COVID-19 condition: how Stichting Long COVID is stimulating research in the Netherlands
:: 30 March 2023    News release
Combatting NCDs and promoting mental health: strong partnership is key
:: 29 March 2023  News release
WHO in Ukraine holds first primary health care conference since the beginning of war

WHO Western Pacific Region
No new digest content identified.

::::::

Disease Outbreak News (DONs)
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

No new digest content identified.

::::::

New WHO Publications
https://www.who.int/publications/i
Selected
31 March 2023
Meeting of the Advisory Committee on Immunization and Vaccines related Implementation Research (IVIR-AC)...

30 March 2023
Considerations for implementing and adjusting public health and social measures in the context of COVID-19
Overview
Public health and social measures have been implemented across the world to reduce SARS-CoV-2 transmission, morbidity, and mortality from COVID-19 and to prevent the overburdening of the health systems and other critical social functions.
Since the last update of this interim guidance, several significant developments have occurred, including increased global population-level immunity against SARS-CoV-2.
As the pandemic continues to evolve, PHSM should be regularly reviewed and adjusted based on ongoing situational assessments at the most local administrative level possible.
This document provides guidance to help Member States assess the severity of the COVID-19 situation and to implement PHSM at different resulting Situational Levels. This updated guidance eliminates the use of categorical transmission classifications with numeric cut-offs as a metric for adjusting PHSM. The guidance further shifts the focus of situational assessment to the dimensions of COVID-19 morbidity/mortality and health system impact (with the latter retained from the previous version). Consequently, the situational level matrix and the wording of each situational level have been updated to take into account these changes.

30 March 2023
WHO SAGE Roadmap for prioritizing uses of COVID-19 vaccines

30 March 2023
Progress on WASH in health care facilities 2000-2021: Special focus on WASH and infection prevention...
28 March 2023

Fostering the responsible use of the life sciences: mitigating biorisks and governing dual-use research

28 March 2023

Regional workshop to operationalize the global guidance framework for the responsible use of the life...

......

CDC/ACIP [U.S.] [to 01 Apr 2023]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html

Latest News Releases
No new digest content identified.

......

ACIP Meetings
Next ACIP Meeting: June 21-22

......

MMWR Weekly
March 31, 2023 / No.13
PDF of this issue

......

Coronavirus Disease 2019 (COVID-19)- CDC
Announcements/reports/data summaries [Selected]
3/29/23
Overall US COVID-19 Vaccine Distribution and Administration Update as of Wed, 29 Mar 2023 06:00:00 EST

......

Africa CDC  [to 01 Apr 2023]
http://www.africacdc.org/
Press Releases
Announcements
Africa CDC at the World Vaccine Congress
Press Releases

Africa CDC Officially Launches Event-based Surveillance Revised Framework, EBS Training Manual and Health Information Exchange Guidelines and Standards
30 March 2023

China CDC
http://www.chinacdc.cn/en/

National Health Commission of the People's Republic of China [to 01 Apr 2023]
http://en.nhc.gov.cn/
News
[Editor’s Note: The most recent post on this site is 24 Dec 2022, representing the last daily report on confirmed COVID-19 infections.]

National Medical Products Administration – PRC [to 01 Apr 2023]
http://english.nmpa.gov.cn/
News
New oral antiviral drug to be used for treatment of COVID-19
2023-03-27
The National Medical Products Administration has recently granted conditional market approval for an oral antiviral drug RAY1216 in a bid to treat COVID-19.

China CDC Weekly Reports: Current Volume (5)
2023-03-31 / No. 13
View PDF of this issue
- Preplanned Studies: Implementing Routine HIV Screening in Hospitals: An Effective Practice to Expand HIV Testing — Xishuangbanna Prefecture, Yunnan Province, China, 2019–2020
- Preplanned Studies: Characteristics of Migration Among HIV-Positive MSM — Guangxi Zhuang Autonomous Region, China, 2005–2021
- Preplanned Studies: Analysis of Knowledge Level and Use of Antiretroviral Pre-Exposure and Post-Exposure Prophylaxis Among MSM — China, 2019–2022

Organization Announcements

Paul G. Allen Frontiers Group [to 01 Apr 2023]
https://alleninstitute.org/news-press/
News
No new digest content identified.
BMGF - Gates Foundation  [to 01 Apr 2023]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
Gates Foundation Launches Make Me Care About Podcast to Highlight People Taking Action to Solve Some of the World’s Toughest Challenges
Press release  Mar 29, 2023

Bill & Melinda Gates Medical Research Institute  [to 01 Apr 2023]
https://www.gatesmri.org/news
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
News: Articles and Publications
No new digest content identified.

CARB-X  [to 01 Apr 2023]
https://carb-x.org/
No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation  [to 01 Apr 2023]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions of Vaccines and Global Health: The Week in Review are available here.
:: Informed Consent: A Monthly Review – March 2023 is now posted here
:: Genomic Medicine – Governance, Ethics, Policy, Practice: A Monthly Digest – March 2023

CEPI – Coalition for Epidemic Preparedness Innovations  [to 01 Apr 2023]
http://cepi.net/
Latest News
No new digest content identified.

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES  [to 01 Apr 2023]
https://cioms.ch/
News; Publications; Events
No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.]  [to 01 Apr 2023]
https://www.darpa.mil/news
News
No new digest content identified.

Duke Global Health Innovation Center [to 01 Apr 2023]
https://dukeghic.org/
Our Blog
No new digest content identified.

EDCTP [to 01 Apr 2023]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
News
30 March 2023
Liberia, Malawi and Zimbabwe join EDCTP Association
EDCTP is pleased to welcome the Republics of Liberia, Malawi and Zimbabwe on board as the newest member countries of the EDCTP Association. Liberia will...

30 March 2023
Dr Detlef Böcking steps down as EDCTP General Assembly representative and technical advisor for Germany
The EDCTP Association would like to express its sincere appreciation to Dr Detlef Böcking, who will in April 2023 be stepping down from his position...

30 March 2023
Second interim evaluation report: EDCTP2 highly relevant in the EU and globally
The European Commission has published the final report of the second interim evaluation of the EDCTP2 programme. The main objective of the evaluation was to...

27 March 2023
EDCTP mourns the loss of Dr Pascoal Mocumbi
It is with deep sadness and sorrow that we announce the passing of Dr Pascoal Mocumbi, EDCTP’s first High Representative, which happened on 25 March...

Emory Vaccine Center [to 01 Apr 2023]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

European Vaccine Initiative [to 01 Apr 2023]
http://www.euvaccine.eu/
Latest News, Events
Evidence Aid  [to 01 Apr 2023]
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.
http://www.evidenceaid.org/

Fondation Merieux  [to 01 Apr 2023]
http://www.fondation-merieux.org/
Support for Laboratories
The BoliLab project, a network of laboratories in the province of Bolikhamxay, reached its conclusion at the end of 2022
March 28, 2023 - Bolikhamxay (Laos)
Led by the Mérieux Foundation with the financial support of LuxDev, the BoliLab project concluded at the end of 2022 with a review of all the actions and achievements over five years of support for health services in the province of Bolikhamxay in Laos...

Gavi  [to 01 Apr 2023]
https://www.gavi.org/
News Releases
No new digest content identified.

GHIT Fund  [to 01 Apr 2023]
https://www.ghitfund.org/newsroom/press
Press Releases
March 30, 2023
A Total of Approximately 400 Million Yen Investment in Eisai, Ehime University, DNDi and Others for New Drug and Vaccine Development for Neglected Tropical Diseases

Global Fund  [to 01 Apr 2023]
News & Stories
30 March 2023
Global Fund Applauds Azerbaijan and Tajikistan for Eliminating Malaria
In a remarkable public health achievement, Azerbaijan and Tajikistan were today certified malaria-free by the World Health Organization (WHO). The certification is granted when a country proves that it has interrupted indigenous transmission of the d...
Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 01 Apr 2023]
https://www.glopid-r.org/news/
News
No new digest content identified.

Hilleman Laboratories  [to 01 Apr 2023]
http://www.hilleman-labs.org/
News & Insights
No new digest content identified.

HHMI - Howard Hughes Medical Institute  [to 01 Apr 2023]
https://www.hhmi.org/news
Press Room
No new digest content identified.

Human Vaccines Project  [to 01 Apr 2023]
http://www.humanvaccinesproject.org/
News
No new digest content identified.

IAVI  [to 01 Apr 2023]
https://www.iavi.org/
Latest News
FEATURES
March 30, 2023
IAVI leaders to participate in World Vaccine Congress

FEATURES
March 27, 2023
IAVI announces renewed support from the Danish government for its HIV prevention program

ICRC  [to 015 Oct 2022]
What's New  [Selected]
No new digest content identified.

INSERM  [to 01 Apr 2023]
https://www.inserm.fr/en/home/
Press Releases
No new digest content identified.
International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
No new digest content identified.

IFFIm
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

IFRC [to 01 Apr 2023]
Press Releases [Selected]
No new digest content identified.

Institut Pasteur [to 01 Apr 2023]
Press Documents
Press release 31.03.2023
Professor Yasmine Belkaid appointed Institut Pasteur President
On March 29, 2023, Professor Yasmine Belkaid was appointed President of the Institut Pasteur by its Board of Governors...

Press release 31.03.2023
The Institut Pasteur and the University of São Paulo sign articles of association to establish the Institut Pasteur in São Paulo
On Friday March 31st, 2023 at a ceremony in Paris, the Institut Pasteur President, Professor Stewart Cole, and the...

ISC / International Science Council [to 01 Apr 2023]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.
Latest Updates
Blogs
The International Science Council welcomes 15 Young Academies and Associations
30.03.2023

International Union of Immunological Societies (IUIS)
https://iuis.org/
Frontiers in Immunology (In-Person & Virtual)
Tuesday 11th April 2023 at New York Academy of Sciences

IVAC  [to 01 Apr 2023]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
No new digest content identified.

IVI  [to 01 Apr 2023]
http://www.ivi.int/
IVI News & Announcements
GVIRF 2023 | A forum for vaccine research and innovation to drive Immunization Agenda 2030
IVI co-organized the fifth Global Vaccine and Immunization Research Forum (GVIRF), a biennial event hosted by WHO, the National Institute of Allergy and Infectious Diseases (NIAID/NIH), and the Bill & Melinda Gates Foundation to track progress and discuss obstacles related to priority vaccine research and development; identify gaps, opportunities, and actions for the vaccine R&D and immunization community; and review progress made toward the Immunization Agenda 2030 (IA2030). This year, GVIRF took place March 28-30 in Incheon, Korea...

Johns Hopkins Center for Health Security  [to 01 Apr 2023]
https://www.centerforhealthsecurity.org/news/center-news/
Center News  [Selected]
No new digest content identified.

MSF/ Médecins Sans Frontières  [to 01 Apr 2023]
http://www.msf.org/
Latest [Selected Announcements]
Yemen
Eight years of war create perfect storm for humanitarian crisis
Voices from the Field 31 Mar 2023

HIV/AIDS
Pharmaceutical company ViiV must provide transparency on HIV prevention drug
Press Release 30 Mar 2023

Türkiye and Syria earthquake response
Northwest Syria: Providing healthcare amongst the rubble in Jindires
Project Update 27 Mar 2023

National Academy of Medicine - USA  [to 01 Apr 2023]
https://nam.edu/programs/
Registration Now Open -- May 24-26 Nobel Prize Summit on Misinformation and Trust in Science

March 19, 2023

Registration is now open for the Nobel Prize Summit 'Truth Trust and Hope' a global conversation on how to stop misinformation from eroding public trust in science. Hosted by NAS and the Nobel Foundation the summit takes place May 24-26 in Washington D.C. and virtually.

PATH appoints Ben Aliwa as new Chief Business and Finance Officer

March 28, 2023 by PATH

Seattle, United States - PATH is pleased to announce that Ben Aliwa is our new Chief Business and Finance Officer. Ben brings over 20 years of sector experience. In his new role, Ben will be responsible for establishing and maintaining strong financial stewardship for growth and impact, optimizing operational efficiency and agility, and strong process automation. This includes overseeing the finance, audit, accounting, IT, facilities, security, travel, and continuous business improvement functions, among others, within a holistic division. Ben has been a part of the PATH team for several years...
UNAIDS [to 01 Apr 2023]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
Press release
UNAIDS welcomes the announcement by Medicines Patent Pool (MPP) and ViiV of three licenses signed with generic manufacturers for long-acting PrEP, and urges further urgent action by ViiV
GENEVA, 31 March 2023

31 March 2023
Healthcare access is fraught for trans people in Asia and the Pacific. Communities are working to change this.

31 March 2023
Beyond transgender visibility: India works toward employment equity

29 March 2023
Improving data collection to improve national AIDS responses

UNICEF [to 01 Apr 2023]
https://www.unicef.org/media/press-releases
No new digest content identified.

Unitaid [to 01 Apr 2023]
https://unitaid.org/
Featured News
No new digest content identified.

Vaccine Equity Cooperative [nee Initiative] [to 01 Apr 2023]
https://vaccineequitycooperative.org/news/
News
No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 01 Apr 2023]
https://www.vaccineacceptance.org/
Announcements, Blog
2nd Annual Vaccination Acceptance Research Network Conference
VARN2023 Registration
Conference dates: June 13-15, 2023
Conference location: Bangkok, Thailand (venue information to come)
**Vaccine Confidence Project**  [to 01 Apr 2023]
http://www.vaccineconfidence.org/
News, Research and Reports

**Do COVID-19 vaccine mandates still make sense?**
Professor Heidi J. Larson speaks to Science about the potential of COVID-19 vaccine mandates to undermine trust in future public health efforts.
March 19, 2023

**Vaccine Education Center – Children’s Hospital of Philadelphia**  [to 01 Apr 2023]
http://www.chop.edu/centers-programs/vaccine-education-center

No new digest content identified.

**Wellcome Trust**  [to 01 Apr 2023]
https://wellcome.ac.uk/news
News. Opinion, Reports
No new digest content identified.

**The Wistar Institute**  [to 01 Apr 2023]
Media

**Press Release**  Mar. 30, 2023

**The Wistar Institute Appoints Legal and Life Sciences Expert Squire Servance to Its Board of Trustees**

**Press Release**  Mar. 28, 2023

**Researchers Identify a Plant-based Compound that Inhibits Reactivation of the HIV Viral Reservoir, Giving the Immune System a Break**
Could be a potential treatment in combination with ART

**WFPHA: World Federation of Public Health Associations**  [to 01 Apr 2023]
https://www.wfpha.org/
Latest News - Blog
No new digest content identified.

**World Medical Association [WMA]**  [to 01 Apr 2023]
Press Releases
No new digest content identified.

**World Organisation for Animal Health (OIE)**  [to 01 Apr 2023]
With complex emergencies threatening global health security, WOAH hosts a first-of-its-kind conference to foster cross-links and dialogue between sectors. Faced by an ever-changing hazard landscape, experts and stakeholders from a variety of sectors will gather at the Global Conference on Emergency Management taking place on 3-5 April in Paris.

::::

**ARM [Alliance for Regenerative Medicine]** [to 01 Apr 2023]

**Selected Press Releases**

**The Alliance for Regenerative Medicine Appoints Rita Johnson-Greene as Chief Operating Officer**
March 21, 2023  Washington, DC

The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization representing the engineered cell therapy and genetic medicines sector, announced the appointment of Rita Johnson-Greene as Chief Operating Officer, effective April 10.

**BIO** [to 01 Apr 2023]

**Press Releases**

**Majority of American Voters Want Congress to Prioritize and Fund Public Health Preparedness, Poll Reveals**
March 30, 2023

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 01 Apr 2023]
http://www.dcvmn.org/

**News; Upcoming events**

*No new digest content identified.*

**ICBA – International Council of Biotechnology Associations** [to 01 Apr 2023]
https://internationalbiotech.org/news/

**News**

*No new digest content identified.*

**IFPMA** [to 01 Apr 2023]
http://www.ifpma.org/resources/news-releases/

**Selected Press Releases, Statements, Publications**

**Position paper**  27 March 2023
No-Fault Compensation (NFC) systems and legislative liability protections for pandemic vaccines
IFPAM, BIO, DCVMN, EFPIA, PhRMA, Vaccines Europe

This joint white paper recommends the implementation of well-designed NFC systems coupled with legislative liability protections for pandemic vaccines to ensure both equitable compensation and adequate vaccine coverage in a future pandemic.

Lessons learned from Covid-19 inform a legal liability framework for pandemic vaccines built to meet the challenges of a future pandemic. NFC systems provide an administrative, non-judicial process for individuals to seek compensation for injuries allegedly linked to vaccines. During a pandemic, effective NFC systems may be essential to ensure equitable compensation and support rapid and continued vaccine coverage. NFC systems should be coupled with legislative liability protections for entities throughout the supply chain whose ability to efficiently develop, distribute, and administer vaccines may be hindered by excessive litigation. We call for governments to implement well-designed NFC systems along with liability protections as essential preparation to respond to the next pandemic threat.


International Alliance of Patients’ Organizations – IAPO [to 01 Apr 2023]
https://www.iapo.org.uk/news/topic/6
Press and media [Selected]

Save the date: 10th Global Patients Congress
We are delighted to announce that IAPO’s 10th Global Patients Congress (GPC 2023) - "Innovative patient partnerships at the heart of global health advancement" will be held on 19 - 20 May 2023 at the Maison Internationale des Associations (MIA) in Geneva, Switzerland as a hybrid event.

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
No new digest announcements identified.

PhRMA [to 01 Apr 2023]
http://www.phrma.org/
Press Releases
No new digest announcements identified.

::::::

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca
Press Releases - No new digest announcements identified

Bharat Biotech
Press Releases - No new digest announcements identified
GSK
Press releases for media
30 March 2023
Medicines Patent Pool signs sublicences with Aurobindo, Cipla and Viatris to produce generic versions of Viiv Healthcare’s innovative long-acting HIV prevention medicine
Licences should enable potentially millions of people living in areas most impacted by HIV to access innovative prevention medicine.

IMBCAMS, China
Home - Website not responding at inquiry

Janssen/JNJ
Press Releases
Janssen Provides Portfolio Update
RARITAN, N.J., March 29, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson disclosed today that following a review of its portfolio to prioritize the most transformational assets for ongoing investment, and an assessment of the respiratory syncytial virus (RSV) vaccine landscape, the
Company will exit its investigational RSV adult vaccine program and discontinue its Phase 3 EVERGREEN study.

The decision to discontinue the Company’s RSV adult vaccine program is part of a broader effort to make strategic choices for its pipeline and research and development (R&D) investments to focus on medicines with the greatest potential benefit to patients. The Company remains committed to investing in internal discovery, development and external innovation across its Therapeutic Areas...

**Merck**

*News releases* - No new digest announcements identified

**Moderna**

*Press Releases*

30 March, 2023

*Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility*

:: Facility to enable access to manufactured mRNA vaccines for Kenya and the African continent, providing health security and building upon Moderna's global public health commitments

:: The facility will be capable of producing up to 500 million doses each year

**Nanogen**

*News* - No new digest announcements identified

**Novartis**

*News* - No new digest announcements identified

**Novavax**

*Press Releases* - No new digest announcements identified

**Pfizer**

*Recent Press Releases* - No new digest announcements identified

**R-Pharm**


[No news or media page identified]

**Sanofi Pasteur**

*Press Releases* - No new digest announcements identified

**Serum Institute of India**

*NEWS & ANNOUNCEMENTS* - No new digest announcements identified

**Sinopharm/WIBPBIBP**

*News* - No new digest announcements identified

**Sinovac**

*Press Releases* - No new digest announcements identified

**SK Biosciences**
Valneva Press Releases
March 30, 2023
Valneva to Present on its Chikungunya Vaccine Candidate and Host a Roundtable at the 23rd World Vaccine Congress in Washington D.C.

Vector State Research Centre of Viralology and Biotechnology
Home - Website not responding [404 error]

WestVac Biopharma Media
Coviccine® --Recombinant COVID-19 Vaccine (Sf9 cell) by WestVac Biopharma is Available for Vaccination in Yunnan
2023-03-28
Recently, the Recombinant COVID-19 Vaccine (Sf9 cell) - Coviccine® developed by WestVac Biopharma Co., Ltd. and West China Hospital of Sichuan University was launched at several vaccination sites in Yunnan...

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.
If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org
Clinicians serving in federal or state government in the United States are accountable to patients, the public, and their professions in ways that transcend clinicians’ typical duties to individual patients and colleagues and even transcend their fiduciary duties to society. One reason for this is that, when clinicians draw upon their professional skill sets to help administer agencies, make laws, or enforce regulations, the social and cultural power they wield as professionals is reified with political power and authority of the state. Clinician governors’ legal and ethical responsibilities extend to preparing, building, and maintaining health sector capacity to deliver quality services equitably in the best of times and during crises. Our lives often depend on how fully clinician governors’ offices are respected and how competently and efficiently their roles are executed.


Rebecca L. Weintraub, Kate Miller, Benjamin Rader, Julie Rosenberg, Shreyas Srinath, Samuel R. Woodbury, Marinanicole D. Schultheiss, Mansi Kansal, Swapnil Vispute, Stylianos Serghiou, Gerardo Flores, Akim Kumok, Tomer Shekel, Evgeniy Gabrilovich, Iman Ahmad, Molly E. Chiang and John S. Brownstein

113(4), pp. 363–367
LAW & ETHICS

Child and Adolescent Health, Health Policy, Sexual Health, Health Law, HIV/AIDS, Adolescent Health, Research Article
Kimberly M. Nelson, Alexandra Skinner, Claire D. Stout, Will Raderman, Emily Unger, Julia Raifman, Madina Agénor, Michele L. Ybarra, Shira I. Dunsiger, S. Bryn Austin and Kristen Underhill
113(4), pp. 397–407

American Journal of Tropical Medicine and Hygiene
Volume 108 (2023): Issue 3 (Mar 2023)
[Reviewed earlier]

Annals of Internal Medicine
March 2023 Volume 176, Issue 3
http://annals.org/aim/issue
[Reviewed earlier]

Artificial Intelligence – An International Journal
Volume 316 March 2023
[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation
http://resource-allocation.biomedcentral.com/
(Accessed 01 Apr 2023)
Cost-effectiveness of COVID-19 vaccination in Latin America and the Caribbean: an analysis in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru
Authors: Augustovski Federico, Bardach Ariel, Santoro Adrián, Rodríguez-Cairolí Federico, López-Osornio Alejandro, Argento Fernando, Havela Maissa, Blumenfeld Alejandro, Bollivian Jamile, Solioz Germán, Capula Analia, López Analía, Cejas Cintia, Savedoff William, Palacios Alfredo, Rubinstein Adolfo...
Content type: Research 1 April 2023

BMJ Global Health
Feb 2023 - Volume 8 - 3
https://gh.bmj.com/content/8/3
[Reviewed earlier]
**Maternal vaccination against pertussis as part of the national immunization program: a qualitative evaluation among obstetric care providers one year after the implementation in December 2019**

Immunization of pregnant women with a tetanus-diphtheria-and-acellular-pertussis (Tdap) vaccine is an effective and safe way to protect infants from pertussis before their primary vaccinations. Vaccine uptake ...

Authors: Maarten M. Immink, Kim van Zoonen, Nina M. Jager, Anne J.M. Pluijmaekers, Hester E. de Melker, Nicoline A.T. van der Maas and Mireille N. Bekker

Citation: BMC Health Services Research 2023 23:311
Content type: Research Published on: 30 March 2023

**Spread and seasonality of COVID-19 pandemic confirmed cases in sub-Saharan Africa: experience from Democratic Republic of Congo, Nigeria, Senegal, and Uganda**

The COVID-19 pandemic has impacted the world negatively with huge health and socioeconomic consequences. This study estimated the seasonality, trajectory, and projection of COVID-19 cases to understand the dyn...

Authors: Ayo S. Adebowale, Rotimi F. Afolabi, Segun Bello, Mobolaji M. Salawu, Eniola A. Bamgboye, Ikeola Adeoye, Magbagbeola D. Dairo, Betty Kivumbi, Irene Wanyana, Ibrahima Seck, Issakha Diallo, Mamadou M. M. Leye, Oumar Bassoum, Mane Fall, Rawlance Ndejjo, Steven N. Kabwama...

Citation: BMC Infectious Diseases 2023 23:187
Content type: Research Published on: 29 March 2023

**Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South Africa**

Respiratory syncytial virus (RSV) causes a substantial burden of acute lower respiratory infection in children under 5 years, particularly in low- and middle-income countries (LMICs). Maternal vaccine (MV) and...

Authors: Mihaly Koltai, Jocelyn Moyes, Bryan Nyawanda, Joyce Nyiro, Patrick K. Munywoki, Stefano Tempia, Xiao Li, Marina Antillon, Joke Bilcke, Stefan Flasche, Philippe Beutels, D. James Nokes, Cheryl Cohen and Mark Jit

Citation: BMC Medicine 2023 21:120
**BMC Pregnancy and Childbirth**
http://www.biomedcentral.com/bmcpregnancychildbirth/content
(Accessed 01 Apr 2023)

**Acceptance of vaccination against pertussis, COVID-19 and influenza during pregnancy: a cross-sectional study**
This study aims to assess the uptake of maternal pertussis and COVID-19 vaccination and the intention towards accepting the maternal influenza vaccination. Insights into different socio-demographic factors rel...
Authors: Veja Widdershoven, Rianne P. Reijis, Annika Eskes, Amanja Verhaegh-Haasnoot and Christian J.P.A. Hoebe
Citation: BMC Pregnancy and Childbirth 2023 23:219
Content type: Research Published on: 30 March 2023

**BMC Public Health**
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 01 Apr 2023)

**Vaccine hesitancy about the HPV vaccine among French young women and their parents: a telephone survey**
The human papillomavirus (HPV) vaccine reduces the burden of cervical and other cancers. In numerous countries, a slow uptake of this vaccine persists, calling for a better understanding of the structural facto...
Authors: Fatima Gauna, Pierre Verger, Lisa Fressard, Marie Jardin, Jeremy K. Ward and Patrick Peretti-Watel
Citation: BMC Public Health 2023 23:628
Content type: Research Published on: 1 April 2023

**Parental hesitancy against COVID-19 vaccination for children and associated factors in Taiwan**
Since July 2021, some countries and regions have initiated the vaccination of minors against coronavirus disease (COVID-19), and parental COVID-19 vaccine hesitancy will affect the vaccination of minors. We ai...
Authors: Jing-Shan Deng, Jau-Yuan Chen, Xiao-Qing Lin, Chun-Lian Huang, Tao-Hsin Tung and Jian-Sheng Zhu
Citation: BMC Public Health 2023 23:571
Content type: Research Published on: 27 March 2023

**Impact of a performance monitoring intervention on the timeliness of Hepatitis B birth dose vaccination in the Gambia: a controlled interrupted time series analysis**
The Hepatitis B virus that can cause liver cancer is highly prevalent in the Gambia, with one in ten babies at risk of infection from their mothers. Timely hepatitis B birth dose administration to protect babi...
Authors: Alieu Sowe, Fredinah Namatovu, Bai Cham and Per E. Gustafsson
Citation: BMC Public Health 2023 23:568
Content type: Research Published on: 27 March 2023
BMC Research Notes
http://www.biomedcentral.com/bmcresnotes/content
(Reviewed earlier)

BMJ Evidence-Based Medicine
April 2023 - Volume 28 - 2
https://ebm.bmj.com/content/28/2
[Reviewed earlier]

BMJ Open
January 2023 - Volume 13 - 1
https://bmjopen.bmj.com/content/13/1
[Reviewed earlier]

Bulletin of the World Health Organization
Volume 101(3); 2023 Mar 1
https://www.ncbi.nlm.nih.gov/pmc/issues/429599/
[Reviewed earlier]

Cell
Mar 30, 2023 Volume 186 Issue 7 p1295-1512
https://www.cell.com/cell/current
[Reviewed earlier]

Child Care, Health and Development
Volume 49, Issue 2 Pages: 211-406 March 2023
https://onlinelibrary.wiley.com/toc/13652214/current
[Reviewed earlier]

Clinical Pharmacology & Therapeutics
Volume 113, Issue 4 Pages: 747-933 April 2023
https://ascpt.onlinelibrary.wiley.com/toc/15326535/current
[Reviewed earlier]

Clinical Therapeutics
January 2023 Volume 45 Issue 1 p1-88
http://www.clinicaltherapeutics.com/current
[Reviewed earlier]
Clinical Trials
Volume 20 Issue 2, April 2023
https://journals.sagepub.com/toc/ctja/20/2
[New issue; No digest content identified]

Conflict and Health
http://www.conflictandhealth.com/
[Accessed 01 Apr 2023]
[No new digest content identified]

Contemporary Clinical Trials
Volume 126 March 2023
[Reviewed earlier]

The CRISPR Journal
Volume 6, Issue 1 / February 2023
https://www.liebertpub.com/toc/crispr/6/1
[Reviewed earlier]

Current Genetic Medicine Reports
Volume 10, issue 3, September 2022
https://link.springer.com/journal/40142/volumes-and-issues/10-3
[Reviewed earlier]

Current Opinion in Infectious Diseases
April 2023 - Volume 36 - Issue 2
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
[Reviewed earlier]

Current Protocols in Human Genetics
Volume 108, Issue 1 December 2020
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current
[Reviewed earlier]

Developing World Bioethics
Volume 23, Issue 1 Pages: 1-87 March 2023
https://onlinelibrary.wiley.com/toc/14718847/current
[Reviewed earlier]
Conflicts of interest

:: Surrogate consent and decisional impairment

Articles

**Legally Effective but Ethically Inadequate: Institutional Review Board Policies for Consent from Legally Authorized Representatives**
Robert R. Harrison
Pages: 14-25
First Published: 27 March 2023

**Research Ethics during Pandemics: How IRBs Can Prepare**
Jacob M. Appel, Ilene Wilets
Pages: 26-34
First Published: 27 March 2023

**Climate change: a bioethical emergency and health priority**
J.C. Macedo
Article 100872

**Quality, integrity and utility of COVID-19 science: opportunities for public health researchers**
Angelo Maria Pezzullo, John P A Ioannidis, Stefania Boccia
European Journal of Public Health, Volume 33, Issue 2, April 2023, Pages 157–158,
https://doi.org/10.1093/eurpub/ckac183

**Vaccination**
**Editor's Choice**
The far-right and anti-vaccine attitudes: lessons from Spain’s mass COVID-19 vaccine rollout
Manuel Serrano-Alarcón, Yuri Wang, Alexander Kentikelenis, Martin Mckee, David Stuckler
European Journal of Public Health, Volume 33, Issue 2, April 2023, Pages 215–221,
https://doi.org/10.1093/eurpub/ckac173

Vaccination barriers and drivers in Romania: a focused ethnographic study
Eve Dube, Adriana Pistol, Aurora Stanescu, Cassandra Butu, Sherine Guirguis ...
European Journal of Public Health, Volume 33, Issue 2, April 2023, Pages 222–227,
https://doi.org/10.1093/eurpub/ckac135

Consumption and tax gains attributable to Covid-19 vaccinations in 12 EU countries with low vaccination rates
Jonathan Cylus, Jessica Walters, Martin McKee, Peter Cowley
European Journal of Public Health, Volume 33, Issue 2, April 2023, Pages 228–234,
https://doi.org/10.1093/eurpub/ckad023

Expert Review of Vaccines
Vol 22 (1) 2023  Issue In Progress
https://www.tandfonline.com/toc/ierv20/current
[Reviewed earlier]

Foreign Affairs
Volume 102, Number 1  January/February 2023
https://www.foreignaffairs.com/issues/2023/102/1
[No new digest content identified]

Forum for Development Studies
Volume 50, 2023 - Issue 1
http://www.tandfonline.com/toc/sfds20/current
[Reviewed earlier]

Genetics in Medicines
Volume 25, Issue 3  March 2023
[Reviewed earlier]

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed 01 Apr 2023]
[No new digest content identified]
Global Health Action
Volume 16, Issue 1 (2023)
https://www.tandfonline.com/toc/zgha20/current?nav=tocList
[Reviewed earlier]

Global Health: Science and Practice (GHSP)
Vol. 11, No. 1  February 28, 2023
http://www.ghspjournal.org/content/current
[Reviewed earlier]

Global Legal Monitor – Library of Congress/USA
https://www.loc.gov/collections/global-legal-monitor/
[Accessed 01 Apr 2023]
[No new digest content identified]

Global Public Health
Volume 18, Issue 1 (2023)
http://www.tandfonline.com/toc/rgph20/current
[Reviewed earlier]

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 01 Apr 2023]
Global health governance performance during Covid-19, what needs to be changed? a delphi survey study
Authors: Wafa Abu El Kheir-Mataria, Hassan El-Fawal and Sungsoo Chun
Content type: Research 31 March 2023

Health and Human Rights
Volume 24, Issue 2, December 2022
Special Section: COVID-19 Vaccine Equity and Human Rights
[Reviewed earlier]

Health Economics, Policy and Law
Volume 18 - Issue 2 - April 2023
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
[Reviewed earlier]

Health Policy and Planning
Volume 38, Issue 3, April 2023
Scaling up task-sharing psychological interventions for refugees in Jordan: a qualitative study on the potential barriers and facilitators

Aniek Woodward, Egbert Sondorp, Alexandra S Barry, Marjolein A Dieleman, Daniela C Fuhr ...

Health Policy and Planning, Volume 38, Issue 3, April 2023, Pages 310–320,
https://doi.org/10.1093/heapol/czad003
[No new digest content identified]

**International Health**
Volume 15, Issue 2, March 2023
https://academic.oup.com/inthealth/issue/15/2
[Reviewed earlier]

**International Human Rights Law Review**
Volume 11 (2022): Issue 2 (Dec 2022)
https://brill.com/view/journals/hrlr/11/2/hrlr.11.issue-2.xml
Table of Contents
[Reviewed earlier]

**International Journal of Community Medicine and Public Health**
Vol. 10 No. 3 (2023): March 2023
[Reviewed earlier]

**International Journal of Epidemiology**
Volume 52, Issue 1, February 2023
https://academic.oup.com/ije/issue

**COVID-19**
**Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales**
Steven Kerr, Stuart Bedston, Declan T Bradley, Mark Joy, Emily Lowthian ...

**Miscellaneous**
**Estimating the excess burden of pertussis disease in Australia within the first year of life, that might have been prevented through timely vaccination**
Duleepa Jayasundara, Deborah Randall, Sarah Sheridan, Vicky Sheppeard, Bette Liu ...

**International Journal of Human Rights in Healthcare**
Volume 16 Issue 1 2023
https://www.emerald.com/insight/publication/issn/2056-4902/vol/16/iss/1
[Reviewed earlier]

**JAMA**
March 28, 2023, Vol 329, No. 12, Pages 961-1040
https://jamanetwork.com/journals/jama/currentissue
[New issue; No digest content identified]
JAMA Health Forum
March 2023, Vol 4, No. 3
https://jamanetwork.com/journals/jama-health-forum/issue
[Reviewed earlier]

JAMA Pediatrics
March 2023, Vol 177, No. 3, Pages 219-324
https://jamanetwork.com/journals/jamapediatrics/currentissue
[Reviewed earlier]

JBI Evidence Synthesis
March 2023 - Volume 21 - Issue 3
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx
[New issue; No digest content identified]

Journal of Adolescent Health
April 2023  Volume 72  Issue 4  p485-646
https://www.jahonline.org/current
[Reviewed earlier]

Journal of Artificial Intelligence Research
Vol. 76 (2023)
https://www.jair.org/index.php/jair
Contents
[Reviewed earlier]

Journal of Community Health
Volume 48, issue 1, February 2023
https://link.springer.com/journal/10900/volumes-and-issues/48-1
[Reviewed earlier]

Journal of Current Medical Research and Opinion
...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.
March 8, 2023  Vol 6, No 03 (2023)
https://www.cmro.in/index.php/jcmro/issue/view/65
Original Research
Knowledge Attitude and Practice on Infection Prevention and Control of Healthcare Workers During Covid-19 In A Tertiary Hospital
Journal of Development Economics
Volume 161  March 2023
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics
Volume 18 Issue 1-2, February-April 2023
http://journals.sagepub.com/toc/jre/current
[Reviewed earlier]

Journal of Epidemiology & Community Health
March 2023 - Volume 77 - 3
https://jech.bmj.com/content/77/3
[Reviewed earlier]

Journal of Evidence-Based Medicine
Volume 15, Issue 4 Pages: 315-424 December 2022
https://onlinelibrary.wiley.com/toc/17565391/current
[Reviewed earlier]

Journal of Global Ethics
Volume 18, Issue 3, 2022
http://www.tandfonline.com/toc/rjge20/current
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 34, Number 1, February 2023
https://muse.jhu.edu/issue/49033
Table of Contents
[Reviewed earlier]

Journal of Immigrant and Minority Health
Volume 25, issue 1, February 2023
Contents
[Reviewed earlier]
Journal of Immigrant & Refugee Studies
Volume 21, 2023  Issue 1
https://www.tandfonline.com/toc/wimm20/current
[Reviewed earlier]

Journal of Infectious Diseases
Volume 227, Issue 3, 1 February 2023
https://academic.oup.com/jid/issue/227/3
[Reviewed earlier]

Journal of International Development
Volume 35, Issue 2  Pages: 199-381  March 2023
https://onlinelibrary.wiley.com/toc/10991328/current
[Reviewed earlier]

Journal of Medical Ethics
March 2023 - Volume 49 - 3
http://jme.bmj.com/content/current
[Reviewed earlier]

Journal of Patient-Centered Research and Reviews
Volume 10, Issue 1 (2023)
https://institutionalrepository.aah.org/jpcrr/
[Reviewed earlier]

Journal of Pediatrics
March 2023  Volume 254  p1-106
http://www.jpeds.com/current
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 01 Apr 2023]
[No new digest content identified]

Journal of Public Health Management & Practice
May/June 2023 - Volume 29 - Issue 3
https://journals.lww.com/jphmp/pages/currentttoc.aspx
[Reviewed earlier]
Electronic nudges to increase influenza vaccination uptake in Denmark: a nationwide, pragmatic, registry-based, randomised implementation trial
Niklas Dyrby Johansen, et al.

The Lancet Child & Adolescent Health
Mar 2023 Volume 7 Number 3 p145-222, e5-e9
https://www.thelancet.com/journals/lanchi/issue/current
[Reviewed earlier]
Lancet Global Health
Mar 2023 Volume 11 Number 3 e301-e474
https://www.thelancet.com/journals/langlo/issue/current
[Reviewed earlier]

Lancet Infectious Diseases
Mar 2023 Volume 23 Number 3 p261-380, e72-e120
https://www.thelancet.com/journals/laninf/issue/current
[Reviewed earlier]

Lancet Public Health
Mar 2023 Volume 8 Number 3 e161-e246
https://www.thelancet.com/journals/lanpub/issue/current
[Reviewed earlier]

Lancet Respiratory Medicine
Mar 2023 Volume 11 Number 3 p213-296, e20-e30
https://www.thelancet.com/journals/lanres/issue/current
[Reviewed earlier]

Maternal and Child Health Journal
Volume 27, issue 2, February 2023
[Reviewed earlier]

Medical Decision Making (MDM)
Volume 43 Issue 3, April 2023
http://mdm.sagepub.com/content/current
[Reviewed earlier]

The Milbank Quarterly
A Multidisciplinary Journal of Population Health and Health Policy
Volume 101, Issue 1 Pages: 1-248 March 2023
https://onlinelibrary.wiley.com/toc/14680009/current
[Reviewed earlier]

Nature
Volume 615 Issue 7954, 30 March 2023
The benefits of scientific collaboration are too often skewed towards wealthier countries. Bioethicists and others present guidance on how stakeholders such as researchers can change this. Lyn Horn, Sandra Alba, Retha G. Visagie
Nature Reviews Immunology
Volume 23 Issue 3, March 2023
https://www.nature.com/nri/volumes/23/issues/3
[Reviewed earlier]

New England Journal of Medicine
March 30, 2023  Vol. 388 No. 13
https://www.nejm.org/toc/nejm/medical-journal
Perspective
End of a Declared Public Health Emergency — Implications for U.S. Emergency Use Authorizations
P.W. Marks, H.D. Marston, and L.R. Baden

Review Article
AI in Medicine: Artificial Intelligence and Machine Learning in Clinical Medicine, 2023
C.J. Haug and J.M. Drazen

Editorials
Artificial Intelligence in Medicine
A.L. Beam and Others

Special Report
AI in Medicine: Benefits, Limits, and Risks of GPT-4 as an AI Chatbot for Medicine
P. Lee, S. Bubeck, and J. Petro

npj Vaccines
https://www.nature.com/npjvaccines/
[Accessed 01 Apr 2023]
[No new digest content identified]

Pediatrics
Volume 151, Issue 3  March 2023
https://publications.aap.org/pediatrics/issue/151/3
[Reviewed earlier]

PharmacoEconomics
Volume 41, issue 3, March 2023
[New issue; No digest content identified]

PLoS Biology
Understanding the barriers and facilitators of COVID-19 vaccine hesitancy amongst healthcare workers and healthcare students worldwide: An umbrella review protocol
Jemma McCready, Dania Comparcini, Bethany Nichol, Mary Steen, John Unsworth, Marco Tomietto
Study Protocol | published 31 Mar 2023 PLOS ONE
https://doi.org/10.1371/journal.pone.0283897

Systematic review of economic evaluations of varicella vaccination programmes
Robert Anderson, Sungwook Kim, Nia Roberts, Stavros Petrou
Research Article | published 27 Mar 2023 PLOS ONE
https://doi.org/10.1371/journal.pone.0282327
**The debate over understanding in AI’s large language models**

We survey a current, heated debate in the artificial intelligence (AI) research community on whether large pretrained language models can be said to understand language—and the physical and social situations language encodes—in any humanlike sense. We ...

Melanie Mitchell and David C. Krakauer

**Research Article** March 20, 2023

**COVID-19 precautionary behaviors and vaccine acceptance among older individuals: The role of close kin**

The family plays a central role in shaping health behaviors of its members through social control and support mechanisms. We investigate whether and to what extent close kin (i.e., partner and children) matter for older people in taking on precautionary ...

Bruno Arpino, Valeria Bordone and Giorgio Di Gessa

**PNAS Nexus**

Volume 2, Issue 3, March 2023

IN PROGRESS

https://academic.oup.com/pnasnexus/issue

[Reviewed earlier]

**Prehospital & Disaster Medicine**

Volume 38 - Issue 2 - April 2023

https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue

[Reviewed earlier]

**Preventive Medicine**

Volume 168 March 2023


[Reviewed earlier]

**Proceedings of the Royal Society B**

29 March 2023 Volume 290 Issue 1995

https://royalsocietypublishing.org/toc/rspb/current

[Reviewed earlier]

**Public Health**

Volume 214 Pages 1-180 (January 2023)


[Reviewed earlier]

**Public Health Ethics**

Volume 15, Issue 3, November 2022
Public Health Reports
Volume 138 Issue 2, March/April 2023
https://journals.sagepub.com/toc/phrg/138/2
[Reviewed earlier]

Qualitative Health Research
Volume 33 Issue 4, March 2023
https://journals.sagepub.com/toc/qhra/current
[New issue; No digest content identified]

Research Ethics
Volume 19 Issue 2, April 2023
http://journals.sagepub.com/toc/reab/current

Topic Piece
Journal editors and publishers’ legal obligations with respect to medical research misconduct
Naomi Holbeach, Ian Freckelton AO QC, Ben W Mol

Open Access Research article First published December 25, 2022 pp. 139–156
The ethics review and the humanities and social sciences: disciplinary distinctions in ethics review processes
Jessica Carniel, Andrew Hickey, Kim Southey, Annette Brömdal, Lynda Crowley-Cyr [...] View all

Topic Piece
Ethical considerations about the collection of biological samples for genetic analysis in clinical trials
Inés Galende-Domínguez, Octavio M Rivero-Lezcano

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 01 Apr 2023]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
Selected Articles
31 Mar 2023
Perspectives of health practitioners on the challenges to accessing sexual and reproductive health care services for Venezuelan migrant women during the COVID-19 pandemic in Quito, Ecuador
Original research | English |

Risk Analysis
Volume 43, Issue 3  Pages: 429-643  March 2023
https://onlinelibrary.wiley.com/toc/15396924/current
[Reviewed earlier]

Risk Management and Healthcare Policy
[Accessed 01 Apr 2023]
[No new digest content identified]

Science
Volume 379| Issue 6639| 31 Mar 2023
https://www.science.org/toc/science/current
Editorial
Fix the backlash against public health
BY Lawrence O. Gostin, Sarah Wetter
30 Mar 2023

Science and Engineering Ethics
Volume 29, issue 1, February 2023
https://link.springer.com/journal/11948/volumes-and-issues/29-1
[Reviewed earlier]

Science Translational Medicine
Volume 15| Issue 689| 29 Mar 2023
https://www.science.org/toc/stm/current
Research Articles
Therapeutic neutralizing monoclonal antibody administration protects against lethal yellow fever virus infection
BY Michael J. Ricciardi, et al.
29 Mar 2023
Therapeutic monoclonal antibodies prevent death from YFV infection in a nonhuman primate model.

Social Science & Medicine
Volume 320  March 2023
[Reviewed earlier]
Therapeutic strategies for human poxvirus infections: Monkeypox (mpox), smallpox, molluscipox, and orf
Erik De Clercq, Yike Jiang, Guangdi Li
Article 102528

Knowledge and vaccination intention of monkeypox in China’s general population: A cross-sectional online survey
Chen Dong, Zhou Yu, Ying Zhao, Xianjie Ma
Article 102533

Monkeypox virus (MPXV) genomics: A mutational and phylogenomic analyses of B.1 lineages
Nicolas Luna, Marina Muñoz, D. Katterine Bonilla-Aldana, Luz H. Patiño, ... Juan David Ramírez
Article 102551
Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis
Atsuyuki Watanabe, Masao Iwagami, Jun Yasuhara, Hisato Takagi, Toshiki Kuno
Pages 1783-1790

Meeting Summary: Global Vaccine and Immunization Research Forum, 2021
Andrew Ford, Angela Hwang, Annie X. Mo, Shahida Baqar, ... B. Fenton Hall
Pages 1799-1807

Comparative performance of between-population vaccine allocation strategies with applications for emerging pandemics
Keya Joshi, Eva Rumpler, Lee Kennedy-Shaffer, Rafia Bosan, Marc Lipsitch
Pages 1864-1874

Concerns about COVID-19 Vaccine Hesitancy among Law Enforcement Officers: Prevalence and Risk Factor Data from a Nationally Representative Sample in the United States
by Bruce G. G. Taylor, et al.
Vaccines 2023, 11(4), 783; https://doi.org/10.3390/vaccines11040783 (registering DOI)
Received: 20 February 2023 / Revised: 29 March 2023 / Accepted: 30 March 2023 / Published: 31 March 2023

Abstract
Scant research exists on COVID-19 vaccine hesitancy among law enforcement officers, hindering health messaging development for officers and, by extension, the communities they serve. This paper's goal was to address this gap by providing the necessary data to better understand hesitancy to guide training and policy interventions for officers. The objective was to conduct the first nationally representative survey of officers on COVID-19 vaccine hesitancy and its correlates. We collected data from February 2021 to March 2022 on officer COVID-19 vaccine hesitancy and examined their responses in terms of sociodemographic factors, health status, and job characteristics. We found that 40% of officers were COVID-19 vaccine hesitant. We found that officers with higher education, older officers, officers with more law enforcement experience, officers who received recent health checkups, and commanders (compared to line officers) were less likely to be COVID-19 vaccine hesitant. Critically, officers working in law enforcement agencies that provided masks for COVID-19 protection were less likely to be COVID-19 vaccine hesitant (compared to agencies not providing masks). Ongoing research is needed to understand how evolving attitudes and barriers toward vaccination change over time for officers and to test messaging to better align officers with health guidelines.
Pre-Print Servers

Gates Open Research
https://gatesopenresearch.org/browse/articles
[Accessed 01 Apr 2023]
Selected Research
Research Article metrics AWAITING PEER REVIEW
Collective norms and modern contraceptive use in men and women: A multilevel analysis of DHS Program data in Nigeria and Zambia [version 1; peer review: awaiting peer review]
Sara Riese, Shireen Assaf, Jeffrey Edmeades, Oluwatoyin Aladejebi, Million Phiri
Peer Reviewers Invited
Funder
United States Agency for International Development
PUBLISHED 28 Mar 2023

Research Article metrics
Revised
Circulation of respiratory viruses during the COVID-19 pandemic in The Gambia [version 3; peer review: 2 approved]
Peer Reviewers Ivy A. Asante; Antonia Ho
Funders
Bill and Melinda Gates Foundation
Global Challenge Research Fund award from The University of Sheffield
UK Research and Innovation grant
LATEST VERSION PUBLISHED 27 Mar 2023

medRxiv
https://www.medrxiv.org/content/about-medrxiv
[Accessed 01 Apr 2023]
[Filter: All articles]
Selected Research

**Multi-ancestry genome-wide study in >2.5 million individuals reveals heterogeneity in mechanistic pathways of type 2 diabetes and complications**
Ken Suzuki, et al
doi: https://doi.org/10.1101/2023.03.31.23287839

**Abstract**

Type 2 diabetes (T2D) is a heterogeneous disease that develops through diverse pathophysiological processes. To characterise the genetic contribution to these processes across ancestry groups, we aggregate genome-wide association study (GWAS) data from 2,535,601 individuals (39.7% non-European ancestry), including 428,452 T2D cases. We identify 1,289 independent association signals at genome-wide significance (P<5x10^-8) that map to 611 loci, of which 145 loci are previously unreported. We define eight non-overlapping clusters of T2D signals characterised by distinct profiles of cardiometabolic trait associations. These clusters are differentially enriched for cell-type specific regions of open chromatin, including pancreatic islets, adipocytes, endothelial, and enteroendocrine cells. We build cluster-specific partitioned genetic risk scores (GRS) in an additional 137,559 individuals of diverse ancestry, including 10,159 T2D cases, and test their association with T2D-related vascular outcomes. Cluster-specific partitioned GRS are more strongly associated with coronary artery disease and end-stage diabetic nephropathy than an overall T2D GRS across ancestry groups, highlighting the importance of obesity-related processes in the development of vascular outcomes. Our findings demonstrate the value of integrating multi-ancestry GWAS with single-cell epigenomics to disentangle the aetiological heterogeneity driving the development and progression of T2D, which may offer a route to optimise global access to genetically-informed diabetes care.

**ChatGPT in Healthcare: A Taxonomy and Systematic Review**
Jianning Li, Amin Dada, Jens Kleesiek, Jan Egger
medRxiv 2023.03.30.23287899; doi: https://doi.org/10.1101/2023.03.30.23287899

**Timing and magnitude of the next wave of COVID-19 in China: lessons from 189 countries and territories**
Beidi Niu, Shuyi Ji, Shi Zhao, Hao Lei
medRxiv 2023.03.27.23287793; doi: https://doi.org/10.1101/2023.03.27.23287793

**Patient engagement in research; benefits, challenges, importance, and implications**
Caitlyn Ivany, Tess Hudson, Patricia Schneider, Hadia Farrukh, Michelle Ghert
medRxiv 2023.03.28.23287870; doi: https://doi.org/10.1101/2023.03.28.23287870

**OSF Pre-prints**
https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences
[Accessed 01 Apr 2023]
[Provider Filter: OSF Pre-prints  Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]

*We observe increasing levels of "posting pollution" by individuals, sometimes posting 10+ items of no value. If this continues, we may decide to no longer monitor this resource.*

No new digest content identified.

Wellcome Open Research

Hai Doan, Jing-Bao Nie

Abstract

Background: A key part of the complexity of actual social life lies in the fact that it operates on a large web of not only prescribed norms and rules, but also explicit and especially implicit expectations which constantly interact with each other.

Methods: This paper offers the first in-depth study on ‘expectations’ in bioethical and health law studies, taking Vietnamese human rights issues in response to coronavirus disease (COVID-19) as illustrations. It defines ‘expectations’ as normative imaginaries that can induce or guide actions and inactions at individual and collective levels.

Results: The study suggests that ‘expectations’ is a fruitful concept for bioethical and health law studies because it helps better understand the complexity of interactions in society and patterns of thinking and acting of actors in real-world contexts. Studying expectations also has implications for how human rights and other ethical norms can be better realized in practice. From applying the concept of ‘expectations’ to study human rights issues in Vietnam, this paper also argues that for better protection of human rights, there must be changes concerning expectations of involved parties.

Conclusions: Changes in expectations in turn call for changes in stimulus, knowledge, praxis, polices, laws and institutions. Meanwhile, checks and balances mechanisms must effectively constrain the materialization of undue expectations.

Governance of adaptive platform trials

Jerome Amir Singh

Abstract

Adaptive Clinical Trials (ACT) differ from conventional clinical trials because they permit continual modifications to key components of trial design during the trial. ACTs have grown in prevalence in recent years, with Adaptive Platform Trials (APTs), in particular, having demonstrated their significant scientific, clinical, and public health utility in relation to the COVID-19 pandemic. There has been a steady increase in the number of regulations and guidelines aimed at guiding the conduct of clinical trials. However, despite the potential of APTs to expedite the testing of new interventions in emergency situations, there is a relative dearth of published literature on why and how such trials should be governed. This work attempts to address this knowledge gap.
In their paper—COVID Credit Policies Around the World: Size, Scope, Costs, and Consequences—the authors discuss the best way to evaluate the size of credit policies in terms of the additional resources they provided to households and businesses and also the cost of credit policies (to make them most comparable with traditional fiscal policies). They also discuss the pros and cons of different policy choices. They apply their suggested methodology to produce new estimates of the amount of additional funding provided by credit and forbearance policies. They then use the estimates to re-evaluate the effective size of government interventions and their potential macroeconomic effects....
No new digest content identified.
CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

**Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).**

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.